Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen

Leukemia and Lymphoma

Volumn 48, Issue 6, 2007, Pages 1119-1126

  Yamanaka, Ryuya ^a,b   Shinbo, Yoshikatsu ^c   Sano, Masakazu ^a   Homma, Jumpei ^a   Tsuchiya, Naoto ^a   Yajima, Naoki ^a   Tamura, Tetsuro ^d   Hondoh, Hiroaki ^e   Takahashi, Hideaki ^a   Morii, Ken ^a   Onda, Kiyoshi ^a   Tanaka, Ryuichi ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Itoigawa General Hospital   (Japan)

^d Niigata Prefectural Central Hospital   (Japan)

^e TOYAMA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Neurotoxicity; Primary CNS lymphoma; Pro MACE MOPP hybrid; Salvage therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PIRARUBICIN; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HUMAN; IMMUNOCOMPETENCE; LUNG TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OVERALL SURVIVAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; RADIATION INJURY; RECURRENT CANCER; SALVAGE THERAPY; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; LYMPHOMA; MALE; MECHLORETHAMINE; METHOTREXATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUROTOXICITY SYNDROMES; PREDNISONE; PROCARBAZINE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 34347359636     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701299564     Document Type: Article

References (26)

1. Abrey, L. E., Yahalom, J. and DeAngelis, L. M. (2000) Treatment for primary CNS lymphoma: The next step. J Clin Oncol, 18, pp. 3144-3150.
2. DeAngelis, L. M., Yahalom, J., Thaler, H. T. and Kher, U. (1992) Combined modality therapy for primary CNS lymphoma. J Clin Oncol, 10, pp. 635-643.
3. Freilich, R. J., Delattre, J. Y., Monjour, A. and DeAngelis, L. M. (1996) Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology, 46, pp. 435-439.
4. Glass, J., Gruber, M. L., Cher, L. and Hochberg, F. H. (1994) Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: Long-term outcome. J Neurosurg, 81, pp. 188-195.
5. O'Brien, P., Roos, D., Pratt, G., Liew, K., Barton, M. and Poulsen, M. (2000) Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol, 18, pp. 519-526.
6. Sandor, V., Stark-Vancs, V., Pearson, D., Nussenblat, R., Whitcup, S. M. and Brouwers, P. (1998) Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol, 16, pp. 3000-3006.
7. Yamanaka, R. and Tanaka, R. (2004) Advances for the treatment of primary central nervous system lymphoma (Review). Oncol Rep, 12, pp. 563-568.
8. Blay, J. Y., Bouhour, D., Carrie, C., Bouffet, E., Brunat-Mentigny, M. and Philip, T. (1995) The C5R protocol: A regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression. Blood, 86, pp. 2922-2929.
9. Brada, M., Hjiyiannakis, D., Hines, F., Traish, D. and Ashley, S. (1998) Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL). Int J Radiat Oncol Biol Phys, 40, pp. 1157-1162.
10. Poortmans, P., Kluin-Nelemans, H. C., Haaxma-Reiche, H., Veer, M Van't, Hansen, M. and Soubeyran, P. (2003) High-Dose Methotrexate-Based Chemotherapy Followed by Consolidating Radiotherapy in Non-AIDS-Related Primary Central Nervous System Lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol, 21, pp. 4483-4488.
11. Abrey, L. E., DeAngelis, L. M. and Yahalom, J. (1998) Long-term survival in primary CNS lymphoma. J Clin Oncol, 16, pp. 859-863.
12. Reni, M., Ferreri, A. J. and Villa, E. (1999) Second-line treatment for primary central nervous system lymphoma. Br J Cancer, 79, pp. 530-534.
13. Cher, L., Glass, J., Harsh, G. R. and Hochberg, F. H. (1996) Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: Preliminary results. Neurology, 46, pp. 1757-1759.
14. Yamanaka, R., Morii, K., Shinbo, Y., Takeuchi, S., Tamura, T. and Hondoh, H. (2005) Modified ProMACE-MOPP Hybrid Regimen with moderate dose methotrexate for Patients with Primary CNS Lymphoma. Ann Hematol, 84, pp. 447-455.
15. Endo, S., Zhang, S. J., Saito, T., Kouno, M., Kuroiwa, T. and Washiyama, K. (2002) Primary malignant lymphoma of the brain: Mutation pattern of rearranged immunoglobulin heavy chain gene. Jpn J Cancer Res, 93, pp. 1308-1316.
16. Bessell, E. M., Graus, F., Lopez-Guillermo, A., Villa, S., Verger, E. and Petit, J. (2001) CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys, 50, pp. 457-464.
17. Omuro, A. M., Ben-Porat, L. S., Panageas, K. S., Kim, A. K., Correa, D. D. and Yahalom, J. (2005) Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol, 62, pp. 1595-1600.
18. Schlegel, U., Pels, H., Glasmacher, A., Kleinschmidt, R., Schmidt-Wolf, I. and Helmstaedter, C. (2001) Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: A pilot study. J Neurol Neurosurg Psychiatry, 71, pp. 118-122.
19. O'Brien, P. C., Roos, D. E., Pratt, G., Liew, K. H., Barton, M. B. and Poulsen, M. G. (2006) Combined-modality therapy for primary central nervous system lymphoma: Long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group). Int J Radiat Oncol Biol Phys, 64, pp. 408-413.
20. Neuwelt, E. A., Goldman, D. L., Dahlborg, S. A., Crossen, J., Ramsey, F. and Roman-Goldstein, S. (1991) Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: Prolonged survival and preservation of cognitive function. J Clin Oncol, 9, pp. 1580-1590.
21. Pels, H., Schmidt-Wolf, I. G., Glasmacher, A., Schulz, H., Engert, A. and Diehl, V. (2003) Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy. J Clin Oncol, 21, pp. 4489-4495.
22. Herrlinger, U., Schabet, M., Brugger, W., Kortmann, R. D., Kuker, W. and Deckert, M. (2002) German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol, 51, pp. 247-252.
23. Plotkin, S. R., Betensky, R. A., Hochberg, F. H., Grossman, S. A., Lesser, G. J. and Nabors, L. B. (2004) Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res, 10, pp. 5643-5646.
24. Fischer, L., Thiel, E., Klasen, H. A., Birkmann, J., Jahnke, K. and Martus, P. (2006) Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol, 17, pp. 1141-1145.
25. Reni, M., Mason, W., Zaja, F., Perry, J., Franceschi, E. and Bernardi, D. (2004) Salvage chemotherapy with temozolomide in primary CNS lymphomas: Preliminary results of a phase II trial. Eur J Cancer, 40, pp. 1682-1688.
26. Enting, R. H., Demopoulos, A., DeAngelis, L. M. and Abrey, L. E. (2004) Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology, 63, pp. 901-903.